CytomX Therapeutics, Inc.: shareholders and insiders

CTMXNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.94

November 17, 2026Market cap $423M

What Ploutos Investor adds for CytomX Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from 2013
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Aug 5, 2026, from their own Form 4 filings.

10 Form 4s

Bought on the market

–

nobody

Sold on the market

$1.2M

4 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan62%
  • The rest38%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $1.2M by 4 people

  • 2025: no buys, no sales
  • 2026: no buys, sold $1.2M by 4 people
  • Aug 3, 2026Alejandra CarvajalChief Legal Officer
    Kind
  • Jun 15, 2026Christopher OgdenChief Financial Officer
    Kind
  • Mar 17, 2026Christopher OgdenChief Financial Officer
    Kind
  • Mar 17, 2026Marcia BelvinSVP, Chief Scientific Officer
    Kind
  • Mar 17, 2026Sean A. McCarthyCEO
    Kind10b5-1
  • Mar 17, 2026Yu-Waye ChuChief Medical Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by CTMX's officers and directors from 2015 up to November 17, 2025, 11 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%Nov 10, 2026 Latest filing
  • FMRwith 1 more person
    Share of class14.6%
  • BlackRock, Inc.
    Share of class7.60%
  • Longitude Capital Partners V, LLCwith 5 more persons
    Share of class7.00%
  • Bank of America
    Share of class5.40%
Fell to 5% or less (11)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • State Street4.10%Nov 10, 202613G
  • Point72 Asset Management, L.P.3.60%Aug 14, 202613G/A
  • Kynam Capital Management, LP9.96%Aug 14, 202613G/A
  • Seven Fleet Master Fund LP0.50%May 15, 202613G/A
  • Venrock Healthcare Capital Partners III, L.P.4.60%May 15, 202613G/A
  • Perceptive Advisors LLC4.60%May 15, 202613G/A
  • The Vanguard Group0.00%Mar 26, 202613G/A
  • Tang Capital Management0.00%Feb 17, 202613G/A
  • OrbiMed Advisors LLC2.10%Feb 17, 202613G/A
  • Biotechnology Value Fund L P3.50%Jul 9, 202513G/A
  • Janus Henderson Group0.00%Feb 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter+10%
  • Citadel Advisors (Griffin)
    In the quarter+125%
  • Millennium Mgmt (Englander)
    In the quarter-84%
  • AQR Capital
    In the quarter+250%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 19.6% of its shares outstanding were held short, +4.8% since the report before.

Shares held short
42.79M
19.6%
Since the report before40.81M on Sep 30, 2026
+4.8%
13.8
3.11M
More days to cover thanof 4,578 US-listed companies with enough volume
97%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 1.26M
  • Nov 15, 2023: Shares held short 1.33M
  • Nov 30, 2023: Shares held short 1.34M
  • Dec 15, 2023: Shares held short 981.6K
  • Dec 29, 2023: Shares held short 1.33M
  • Jan 12, 2024: Shares held short 1.32M
  • Jan 31, 2024: Shares held short 1.25M
  • Feb 15, 2024: Shares held short 1.30M
  • Feb 29, 2024: Shares held short 1.64M
  • Mar 15, 2024: Shares held short 3.53M
  • Mar 28, 2024: Shares held short 3.32M
  • Apr 15, 2024: Shares held short 3.59M
  • Apr 30, 2024: Shares held short 3.60M
  • May 15, 2024: Shares held short 8.75M
  • May 31, 2024: Shares held short 7.90M
  • Jun 14, 2024: Shares held short 7.76M
  • Jun 28, 2024: Shares held short 8.05M
  • Jul 15, 2024: Shares held short 7.74M
  • Jul 31, 2024: Shares held short 7.74M
  • Aug 15, 2024: Shares held short 7.87M
  • Aug 30, 2024: Shares held short 7.15M
  • Sep 13, 2024: Shares held short 6.98M
  • Sep 30, 2024: Shares held short 6.25M
  • Oct 15, 2024: Shares held short 6.07M
  • Oct 31, 2024: Shares held short 5.67M
  • Nov 15, 2024: Shares held short 4.44M
  • Nov 29, 2024: Shares held short 4.39M
  • Dec 13, 2024: Shares held short 5.54M
  • Dec 31, 2024: Shares held short 4.80M
  • Jan 15, 2025: Shares held short 4.63M
  • Jan 31, 2025: Shares held short 4.55M
  • Feb 14, 2025: Shares held short 4.40M
  • Feb 28, 2025: Shares held short 4.70M
  • Mar 14, 2025: Shares held short 9.00M
  • Mar 31, 2025: Shares held short 9.36M
  • Apr 15, 2025: Shares held short 9.57M
  • Apr 30, 2025: Shares held short 9.74M
  • May 15, 2025: Shares held short 17.73M
  • May 30, 2025: Shares held short 18.96M
  • Jun 13, 2025: Shares held short 20.79M
  • Jun 30, 2025: Shares held short 22.39M
  • Jul 15, 2025: Shares held short 23.87M
  • Jul 31, 2025: Shares held short 23.96M
  • Aug 15, 2025: Shares held short 25.14M
  • Aug 29, 2025: Shares held short 26.97M
  • Sep 15, 2025: Shares held short 28.96M
  • Sep 30, 2025: Shares held short 31.37M
  • Oct 15, 2025: Shares held short 28.40M
  • Oct 31, 2025: Shares held short 28.73M
  • Nov 14, 2025: Shares held short 29.32M
  • Nov 28, 2025: Shares held short 17.19M
  • Dec 15, 2025: Shares held short 16.77M
  • Dec 31, 2025: Shares held short 23.70M
  • Jan 15, 2026: Shares held short 16.12M
  • Jan 30, 2026: Shares held short 14.81M
  • Feb 13, 2026: Shares held short 16.96M
  • Feb 27, 2026: Shares held short 18.86M
  • Mar 13, 2026: Shares held short 20.42M
  • Mar 31, 2026: Shares held short 22.03M
  • Apr 15, 2026: Shares held short 27.52M
  • Apr 30, 2026: Shares held short 29.74M
  • May 15, 2026: Shares held short 31.13M
  • May 29, 2026: Shares held short 28.72M
  • Jun 15, 2026: Shares held short 30.61M
  • Jun 30, 2026: Shares held short 35.57M
  • Jul 15, 2026: Shares held short 40.32M
  • Jul 31, 2026: Shares held short 35.11M
  • Aug 14, 2026: Shares held short 34.62M
  • Aug 31, 2026: Shares held short 33.51M
  • Sep 15, 2026: Shares held short 38.64M
  • Sep 30, 2026: Shares held short 40.81M
  • Oct 15, 2026: Shares held short 42.79M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading45.7% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 45.7% of the shares in the reported trades were short sales, against 60.6% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
45.7%
The 14 beforeOct 9, 2026 – Oct 28, 2026
60.6%
Change
-14.9 pts
Short sales a dayon average, of 2.27M shares
1.04M
More than atof 3,666 US-listed companies, same days
35%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 55.9%
  • Oct 12, 2026: Short sales 73.3%
  • Oct 13, 2026: Short sales 73.3%
  • Oct 14, 2026: Short sales 62.8%
  • Oct 15, 2026: Short sales 64.8%
  • Oct 16, 2026: Short sales 68.5%
  • Oct 19, 2026: Short sales 68%
  • Oct 20, 2026: Short sales 70.4%
  • Oct 21, 2026: Short sales 67.2%
  • Oct 22, 2026: Short sales 27.3%
  • Oct 23, 2026: Short sales 46.8%
  • Oct 26, 2026: Short sales 66.1%
  • Oct 27, 2026: Short sales 47.8%
  • Oct 28, 2026: Short sales 51.9%
  • Oct 29, 2026: Short sales 72.6%
  • Oct 30, 2026: Short sales 74.5%
  • Nov 2, 2026: Short sales 49.3%
  • Nov 3, 2026: Short sales 55.4%
  • Nov 4, 2026: Short sales 72.5%
  • Nov 5, 2026: Short sales 52.7%
  • Nov 6, 2026: Short sales 43.7%
  • Nov 9, 2026: Short sales 32.1%
  • Nov 10, 2026: Short sales 19.2%
  • Nov 11, 2026: Short sales 54.9%
  • Nov 12, 2026: Short sales 56%
  • Nov 13, 2026: Short sales 66.5%
  • Nov 16, 2026: Short sales 49.1%
  • Nov 17, 2026: Short sales 53.3%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

2.20M Insiders' shares1.30% Of the company
  • Sean A. McCarthyCEO
    Directly1.08M
  • Marcia BelvinSVP, Chief Scientific Officer
    Directly300.8K
  • Christopher OgdenChief Financial Officer
    Directly295.3K
  • Yu-Waye ChuChief Medical Officer
    Directly189.4K
  • Lloyd A RowlandGeneral Counsel
    Directly120.6K
  • Jeffrey B LandauChief Business Officer
    Directly119.1K
  • Alejandra CarvajalChief Legal Officer
    Directly100.0K

A lower bound: it counts only the 7 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

15 ETFs holding it0.28% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.28%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.17%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.15%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.05%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.02%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.02%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.02%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.02%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%

15 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

179 Managers, Q2 2026$800M Value of their positions
  • Q3 2025: Managers 103
  • Q4 2025: Managers 122
  • Q1 2026: Managers 180
  • Q2 2026: Managers 179

Institutional investors by quarter

The fund managers holding CTMX, quarter by quarter, from Q4 2015 to Q2 2025, 39 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 179 managers held 213M shares, worth $800M. During the quarter 47 opened a position, 48 closed one, 70 added and 32 trimmed.

The largest holders, Q2 2026

  • FMR
    In the quarter+2.4%
  • Kynam Capital Management
    In the quarter+45%
  • BlackRock
    In the quarter+236%
  • Bank of America
    In the quarter+48%
  • State Street
    In the quarter+107%
  • Perceptive Advisors
    In the quarter+3.4%
  • Vanguard Capital Management
    In the quarter-2.4%
  • Point72 (Cohen)
    In the quarter-0.8%
  • Wellington Management Group
    In the quarter+44%
  • Venrock Adviser
    In the quarter-50%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do CytomX Therapeutics's filings show?

Who buys and sells is one part of CytomX Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CTMX's shareholders

Didn't find what you were looking for?

Ask us
Have CTMX's insiders bought or sold?

From Jun 17, 2026 to Aug 5, 2026 CytomX Therapeutics's insiders bought 0 and sold $5.0K of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold CTMX?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $23M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.